mk 0663 has been researched along with Kidney Failure, Chronic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arefin, S; Jahan, J; Jakobsson, PJ; Korotkova, M; Kublickiene, K; Larsson, K; Mudrovcic, N; Steinmetz-Späh, J; Stenvinkel, P; Wennberg, L | 1 |
| Agrawal, NG; Alcorn, H; Cho, M; Cote, J; Geer, LA; Gottesdiener, KM; Kline, WF; Marbury, TC; Matthews, CZ; Mazenko, RS; Moncrief, JW; Petty, KJ; Porras, AG; Robson, RA; Sack, MR; Schwartz, JI; Swan, S; Wong, PH; Woolf, EJ | 1 |
2 other study(ies) available for mk 0663 and Kidney Failure, Chronic
| Article | Year |
|---|---|
Effects of microsomal prostaglandin E synthase-1 inhibition on resistance artery tone in patients with end stage kidney disease.
Topics: Adrenergic Agents; Arteries; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Etoricoxib; Humans; Kidney Failure, Chronic; Microvessels; Nitrobenzenes; Prostaglandin-E Synthases; Prostaglandins; Sulfonamides | 2022 |
Pharmacokinetics of etoricoxib in patients with renal impairment.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Biological Availability; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Etoricoxib; Female; Half-Life; Humans; Kidney Failure, Chronic; Male; Metabolic Clearance Rate; Middle Aged; Protein Binding; Pyridines; Renal Dialysis; Sulfones | 2004 |